Ibrutinib may impair serological responses to influenza vaccination

Documenti analoghi

• Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
  di: Tam, Constantine S., et al.
  Pubblicazione: (2016)
• 1578. Back to Bactrim–Utilizing Preferred Prophylaxis Strategies in Immunocompromised Hosts Via a Trimethoprim-Sulfamethoxazole Rechallenge Program
  di: Smibert, Olivia, et al.
  Pubblicazione: (2018)
• Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
  di: Borge, Mercedes, et al.
  Pubblicazione: (2015)
• 1787. The Safety and Efficacy of an Oral Penicillin Rechallenge Program in Cancer Patients: A Pilot Multicenter Study
  di: Smibert, Olivia, et al.
  Pubblicazione: (2018)
• The Safety of Antibiotic Skin Testing in Severe T-cell-Mediated Hypersensitivity of immunocompetent and immunocompromised hosts.
  di: Trubiano, Jason A, et al.
  Pubblicazione: (2018)